Meningioma - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Meningioma - Pipeline Review, H1 2016', provides an overview of the Meningioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Meningioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Meningioma - The report reviews pipeline therapeutics for Meningioma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Meningioma therapeutics and enlists all their major and minor projects - The report assesses Meningioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Meningioma Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Meningioma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Meningioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Meningioma Overview 6 Therapeutics Development 7 Pipeline Products for Meningioma - Overview 7 Pipeline Products for Meningioma - Comparative Analysis 8 Meningioma - Therapeutics under Development by Companies 9 Meningioma - Therapeutics under Investigation by Universities/Institutes 10 Meningioma - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Meningioma - Products under Development by Companies 13 Meningioma - Products under Investigation by Universities/Institutes 14 Meningioma - Companies Involved in Therapeutics Development 15 Arno Therapeutics, Inc. 15 Boehringer Ingelheim GmbH 16 e-Therapeutics Plc 17 GlaxoSmithKline Plc 18 Novartis AG 19 Pfizer Inc. 20 Pharma Mar, S.A. 21 Progenics Pharmaceuticals, Inc. 22 Meningioma - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 afatinib dimaleate - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 AR-42 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Edotreotide Labeled Yttrium 90 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 ETS-2101 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 GSK-2256098 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 HXR-9 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 pasireotide - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 sunitinib malate - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 trabectedin - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Meningioma - Recent Pipeline Updates 60 Meningioma - Dormant Projects 79 Meningioma - Product Development Milestones 80 Featured News & Press Releases 80 Sep 21, 2015: Enrollment of first patient in a Phase II trabectedin study in brain tumor type called meningioma 80 Jun 07, 2012: Arno Therapeutics Announces Additional Orphan-Drug Designations For AR-42 In Europe 80 Feb 21, 2012: Arno Therapeutics Receives Two Orphan-Drug Designations For AR-42 To Treat Central-Nervous-System Tumors 81 Appendix 82 Methodology 82 Coverage 82 Secondary Research 82 Primary Research 82 Expert Panel Validation 82 Contact Us 82 Disclaimer 83
List of Tables
Number of Products under Development for Meningioma, H1 2016 7 Number of Products under Development for Meningioma - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Meningioma - Pipeline by Arno Therapeutics, Inc., H1 2016 15 Meningioma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 16 Meningioma - Pipeline by e-Therapeutics Plc, H1 2016 17 Meningioma - Pipeline by GlaxoSmithKline Plc, H1 2016 18 Meningioma - Pipeline by Novartis AG, H1 2016 19 Meningioma - Pipeline by Pfizer Inc., H1 2016 20 Meningioma - Pipeline by Pharma Mar, S.A., H1 2016 21 Meningioma - Pipeline by Progenics Pharmaceuticals, Inc., H1 2016 22 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Stage and Target, H1 2016 25 Number of Products by Stage and Mechanism of Action, H1 2016 27 Number of Products by Stage and Route of Administration, H1 2016 29 Number of Products by Stage and Molecule Type, H1 2016 31 Meningioma Therapeutics - Recent Pipeline Updates, H1 2016 60 Meningioma - Dormant Projects, H1 2016 79
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.